ArticleBJU international2019
Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study.
Article in BJU international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- ERN GENTURIS clinical practice guidelines for the diagnosis, surveillance and management of people with Birt-Hogg-Dubé syndrome.European journal of human genetics : EJHG · 2024Guideline
- Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1-a systematic review.Systematic reviews · 2022Pooled it
- Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic.World journal of urology · 2021Pooled it
- Pooled it
- Decision regret after partial nephrectomy for benign small renal masses: The importance of preoperative counselling.BJUI compass · 2026Article
- Delayed Partial Nephrectomy After Renal Cryoablation: Whole-Lesion Histology and Clinical Course of a Single Case.Journal of clinical medicine · 2026Article
- Management of urinary fistulas after partial nephrectomy: results from the U-LEAK study (UroCCR-181).World journal of urology · 2026Observational
- The decline of radical nephrectomy: Contemporary trends in the treatment of T1 renal cell carcinoma.BJUI compass · 2026Article
- Outcomes After Initial Noninterventional Management of Clinical Stage cT1b Renal Masses.European urology open science · 2026Article
- Long-term Clinical Outcomes of Radiofrequency Ablation for Pathologically Diagnosed T1a Renal Cell Carcinoma: A 10-Year Single-center Experience.Interventional radiology (Higashimatsuyama-shi (Japan) · 2026Article
- Current controversies with active surveillance management of small renal masses.Mini-invasive surgery · 2026Article
- Contemporary assessment of diagnostic performance and histologic concordance of renal mass biopsy with surgical pathology.BJUI compass · 2025Article
- Advances in renal cancer: diagnosis, treatment, and emerging technologies.La Radiologia medica · 2025Review
- [A retrospective matching study of partial nephrectomy and radical nephrectomy for pathological T3a stage renal cell carcinoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025Article
- Extracellular vesicle-derived microRNAs in renal cell carcinoma: biological roles and clinical applications.Frontiers in cell and developmental biology · 2025Review
- A comparative analysis of fear of cancer recurrence in patients with small renal masses: Active surveillance versus cryoablation.Acta oncologica (Stockholm, Sweden) · 2024Article
- The evolving management of small renal masses.Nature reviews. Urology · 2024Review
- Image-Guided Ablation of Renal Masses: Challenges to Produce High-Quality Evidence and Future Directions.Seminars in interventional radiology · 2024Review
- Nephrectomy and IVC thrombectomy in renal cancer: a narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Ablative or Surgical Treatment for Small Renal Masses (T1a): A Single-Center Comparison of Perioperative Morbidity and Complications.Current oncology (Toronto, Ont.) · 2024Observational
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
objectivesTo explore the comparative effectiveness of partial nephrectomy (PN), radical nephrectomy (RN), ablative therapies (ablation) and active surveillance (AS) for small renal masses (SRMs; tumour diameter ≤4.0 cm) in the domains of survival, renal function and quality of life (QoL) using the prospectively maintained Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry. PATIENTS AND
methodsEstimated glomerular filtration rate (eGFR) was calculated from creatinine values to determine renal function. QoL was measured using the Short Form 12 (SF-12) questionnaire. The Kaplan-Meier method and Cox proportional hazards regression were used for survival analysis. The mixed-effects model was used for renal function and QoL analysis.
resultsOf 638 patients, 231 (36.2%) chose PN, 41 (6.4%) RN, 27 (4.2%) ablation and 339 (53.1%) AS. Cancer-specific survival at 7 years was 98.8% in PN patients and 100% in all other groups. Overall survival (OS) at 7 years was 87.9%, 90.2%, 83.5% and 66.1% in PN, RN, ablation and AS patients, respectively. The OS rate was significantly worse in the AS group than other groups and likely attributable to older age and increased comorbidities. The eGFR was lowest in RN patients but comparable in all other groups. QoL was lowest in AS patients due to lower physical health scores, but mental health scores were similar in all groups.
conclusionsWith excellent oncological outcomes in all groups, nephron-sparing approaches, like PN and ablation, are preferred over RN when intervention is indicated for SRMs. AS is a reasonable option for select patients, given the comparable oncological and mental health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.